- Home
- KTTA
KTTA
Pasithea Therapeutics Corp.
as 03-28-2025 4:00pm EST
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | MIAMI BEACH |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 75.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.92 - $9.25 | Next Earning Date: | 03-24-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Pasithea Therapeutics Corp. News
KTTA Breaking Stock News: Dive into KTTA Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference
MT Newswires
2 months ago
Top Midday Gainers
MT Newswires
2 months ago
Top Premarket Gainers
GlobeNewswire
2 months ago
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
GlobeNewswire
3 months ago
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4
GlobeNewswire
4 months ago
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
GlobeNewswire
6 months ago
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
MT Newswires
6 months ago
Sector Update: Health Care Stocks Mixed Late Afternoon
Compare KTTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KTTA Pasithea Therapeutics Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.